Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gary Johnson, M.D.
University of Kansas Medical Center
Principal Investigator - Julia Chapman, M.D.
University of Kansas Medical Center
Principal Investigator - Kathleen Moore, MD
Peggy and Charles Stephenson Oklahoma Cancer Center
Principal InvestigatorKOL profile → - Thomas K Schulz, M.D.
Cancer Center of Kansas
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Kansas Medical Center
Kansas City, Kansas, United States
- Cancer Center of Kansas
Wichita, Kansas, United States
- Peggy and Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 31 May 2013
- Completion
- 31 May 2013
- Last update posted
- 27 Feb 2014
- Registered enrollment
- 22
- Registry id
- NCT00666991
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.